Jennifer Garner Joins the EB Community to Dream of a World Beyond EB
WATCH HERE:
A world beyond EB is a world that is more limitless. A world beyond EB is a happy place. Together we can achieve a world beyond EB.
We’re so thankful for Jennifer Garner for helping us raise $6M over the last 3 years of Venture into Cures to fund research and accelerate treatments and cures for Epidermolysis Bullosa (EB). Estimated to affect 500,000 around the world, EB is a group of rare, life-threatening skin diseases marked by fragile skin that easily breaks and blisters. The skin is so fragile that even gentle rubbing or accidental pressure can cause it to tear. For this reason, children with EB are sometimes called “butterfly” children, because their skin is as fragile as a butterfly’s wings.
EBRP was co-founded by a group of parents dedicated to savings their kids’ lives, along with Jill and Eddie Vedder, and is the largest global organization supporting research for EB. Since its foundation, EBRP has raised $50M, funded more than 120 projects, and increased clinical research for EB by nearly 20 times, including four Phase 3 clinical trials.
We’re so thankful for Jennifer Garner for helping us raise $6M over the last 3 years of Venture into Cures to fund research and accelerate treatments and cures for Epidermolysis Bullosa (EB). Estimated to affect 500,000 around the world, EB is a group of rare, life-threatening skin diseases marked by fragile skin that easily breaks and blisters. The skin is so fragile that even gentle rubbing or accidental pressure can cause it to tear. For this reason, children with EB are sometimes called “butterfly” children, because their skin is as fragile as a butterfly’s wings.
EBRP was co-founded by a group of parents dedicated to savings their kids’ lives, along with Jill and Eddie Vedder, and is the largest global organization supporting research for EB. Since its foundation, EBRP has raised $50M, funded more than 120 projects, and increased clinical research for EB by nearly 20 times, including four Phase 3 clinical trials.
